This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.
Stocks · News reference
TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wolfe Research Downgrades Roivant Sciences to Peer Perform
Wolfe Research analyst Andy Chen downgrades Roivant Sciences (NASDAQ:ROIV) from Outperform to Peer Perform.
Transcript: Roivant Sciences Q1 2027 Earnings Conference Call
On Thursday, Roivant Sciences (NASDAQ:ROIV) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Immunovant Ends Autoimmune Skin Disorder Program
Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.